CClinicalTrials.gg
CompletedNCT01162018Updated Apr 4, 2019

Acupuncture for Sleep Disruption in Cancer Survivors

An interventional study of acupuncture and placebo in Sleep Initiation and Maintenance Disorders and Breast Cancer, sponsored by Stanford University. Completed at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-04.

Sponsored by Stanford University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

The proposed study will recruit 60 women with breast cancer who finished undergoing treatment who complain of persistent insomnia problems that began with onset of their cancer diagnosis. The eligible women would be randomized and stratified by sleep problems to two arms: (Acupuncture Arm vs. Sham Acupuncture) with a goal of having 48 patients complete the study (we anticipate about 20% attrition rate). The study interventions will begin after patients completed their treatment. The placebo control for acupuncture will be a validated sham acupuncture control Assessments will be made with daily diaries and with weekly questionnaires. PSG data will be collected on the subsample of the population. Data will be gathered via pencil-and-paper measures before, during, immediately following, one month following the completion of treatment and six months after the conclusion of treatment. In addition, actigraphy data (objective sleep continuity data) will be acquired prior to and following treatment

02

Conditions studied

  • Sleep Initiation and Maintenance Disorders
  • Breast Cancer
03

In context

Sleep Initiation and Maintenance Disorders

1,855 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 593 are open to participants now.

This study's enrollment of 65 is below the median of 73 across 1,631 interventional studies indexed under Sleep Initiation and Maintenance Disorders.

Browse Sleep Initiation and Maintenance Disorders studies →

Lead sponsor

Stanford University is the lead sponsor of 2,117 studies on the registry; 425 are open to participants now.

Of its 259 completed or terminated interventional studies of FDA-regulated products, 197 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Females diagnosed with breast cancer who are not currently undergoing cancer treatment (hormonal treatment is permitted).
  • The last cancer treatment ≥ 2 weeks prior to screening.
  • ≥ 21 years of age.
  • Able to understand written and spoken English.
  • Have a habitual bedtime between 9:00 pm and 3:00 am and a habitual rise time between 4:00 am and 11 am.
  • Meet DSM-IV criteria for insomnia (determined by the of the Duke Structured Interview of Sleep Disorders) with duration ≥ 1 month by Screening.
  • Willingness to discontinue the use of any current sleep aides (prescription, OTC, or naturopathic agents).
  • Properly executed Informed Consent.
  • Karnofsky Performance Scale Index score ≥ to 70, (patients who score between 61-69 might be included per PI's evaluation).
  • Insomnia Severity Index (ISI) > 8 at Screening.
  • Able to travel to Stanford University and vicinity for assessments and acupuncture treatments.

Exclusion criteria

Exclusion Criteria:

  • Unstable medical or psychiatric illness (eMINI, current or within the last 5 years).
  • Exposure to acupuncture within 6 months prior to screening.
  • Currently pregnant or nursing.
  • History of substance abuse or meet criteria for current alcohol abuse or dependence.
  • Center for Epidemiological Studies Depression Scale (CES-D) >27 at Screening. Meet criteria for sleep apnea, restless legs syndrome or Circadian Rhythm Sleep Disorder on the basis of the Duke Structured Interview of Sleep Disorders (DSISD) or STOP-BANG is ≥ to 3.
  • Major surgery within 4 weeks prior to first acupuncture treatment.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Acupuncture Arm

    Procedure: acupuncture

  • Sham comparator
    Sham Acupuncture

    Sham Acupuncture

    Other: placebo

Interventions

  • Procedureacupuncture

    The eligible women would be randomized and stratified by sleep problems to two arms: (Acupuncture Arm vs. Sham Acupuncture) with a goal of having 48 patients complete the study (we anticipate about 20% attrition rate). The study interventions will begin after patients completed their treatment. The placebo control for acupuncture will be a validated sham acupuncture control Assessments will be made with daily diaries and with weekly questionnaires. There are ten sessions each lasting approximately 20 minutes. All participants will have PSG data collected.

  • Otherplacebo
06

What researchers measure

Primary outcomes

  1. Fatigue reduction

    Time frame: 1 month and 3 months post final acupuncture treatment

  2. Quality of life in breast cancer survivors after acupuncture

    Quality of life in breast cancer survivors after acupuncture will be measured through questionnaire using 28 item scale of functional assessment of chronic illness therapy- fatigue subscale (FACIT-F) version 4. Total score ranges from 0 to 108. A higher score indicates better quality of life.

    Time frame: 1 month and 6 months post final acupuncture treatment

  3. Insomnia reduction

    Time frame: 1 month and 3 months post final acupuncture treatment

07

Study locations

1 site
  • Stanford University School of Medicine
    Stanford, California 94305, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01162018
Lead sponsor
Stanford University
Collaborators
National Institutes of Health (NIH), National Center for Complementary and Integrative Health (NCCIH)
Responsible party
David Spiegel (Jack, Samuel and Lulu Willson Professor in Medicine, Stanford University) — Principal investigator
First posted
Jul 14, 2010
Start date
Feb 2011
Primary completion
Jul 2012
Completion
Aug 2012
Last update
Apr 4, 2019

Study contacts

David Spiegel
principal investigator · Stanford University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion